SafeHeal Clinches €35M Series C to Pioneer Ostomy-Free Solutions in Colorectal Surgery

SafeHeal, a pioneering clinical stage medical device manufacturer based in France and established in 2015, is thrilled to announce the successful raising of €35,000,000 in its latest funding round. This significant financial boost marks a major milestone for the company as it continues to innovate and transform the field of colorectal surgery. Specializing in the development of anastomosis protection devices, SafeHeal has built its reputation on groundbreaking solutions that address critical challenges in surgical procedures. Its flagship product, Colovac, is designed to eliminate the need for diverting ostomies in patients undergoing colectomy—a revolutionary step that promises to enhance patient outcomes and streamline post-operative recovery processes. The newly secured funding will be strategically deployed to accelerate the next phase of clinical development and commercialization of Colovac. Investments will be directed toward comprehensive clinical trials, as well as expanding manufacturing capabilities to meet growing global demand. The infusion of capital will also enable SafeHeal to further refine and enhance the technology underpinning its innovative device portfolio, ensuring that its products continue to meet the highest standards of safety and efficacy. Additionally, part of the funds will be allocated to strengthening regulatory support and commercial partnerships, positioning the company for sustained success in competitive international markets. This funding announcement not only underscores investor confidence in SafeHeal’s innovative approach to colorectal surgery but also signals a promising future where fewer patients will have to endure the complications associated with traditional surgery methods. With a strong commitment to transforming surgical care, SafeHeal is poised to redefine the landscape of colorectal surgery and bring about meaningful improvements in patient health worldwide.